Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population

Journal of Oral Pathology and Medicine

Volumn 39, Issue 2, 2010, Pages 155-161

  Wang, Li Hsuan ^a   Ting, Shuo Chun ^a,b   Chen, Chung Ho ^a   Tsai, Chi Cheng ^a,b   Lung, Oliver ^c   Liu, Ta Chih ^a   Lee, Chia Wen ^b   Wang, Yen Yun ^b   Tsai, Chin Ling ^d   Lin, Ying Chu ^b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c CANADIAN FOOD INSPECTION AGENCY   (Canada)

^d KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

Author keywords

FAS; FAS ligand; Malignant potential; Oral cancer; Oral submucous fibrosis

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; ALCOHOL CONSUMPTION; APOPTOSIS; ARTICLE; BETEL NUT; CANCER RISK; CORRELATION ANALYSIS; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LEUKOPLAKIA; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; TAIWAN;

ADENOSINE; ALCOHOL DRINKING; ANTIGENS, CD95; APOPTOSIS; ARECA; CARCINOMA, SQUAMOUS CELL; CYTOSINE; FAS LIGAND PROTEIN; FEMALE; GENETIC VARIATION; GUANINE; HAPLOTYPES; HUMANS; LEUKOPLAKIA, ORAL; MALE; MIDDLE AGED; MOUTH NEOPLASMS; ORAL SUBMUCOUS FIBROSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECANCEROUS CONDITIONS; RISK FACTORS; SMOKING; TAIWAN; THYMINE;

EID: 76249125939     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2009.00873.x     Document Type: Article

References (34)

1. Sawhney M, Rohatgi N, Kaur J, et al. Expression of NF-kappaB parallels COX-2 expression in oral precancer and cancer: association with smokeless tobacco. Int J Cancer 2007 120: 2545 2556.
2. Department of Health. Health and vital statistics, Republic of China 2007. Taiwan, ROC: Department of Health Executive Yuan, 2008.
3. Mithani SK, Mydlarz WK, Grumbine FL, Smith IM, Califano JA. Molecular genetics of premalignant oral lesions. Oral Dis 2007 13: 126 133.
4. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001 411: 342 348.
5. Crew KD, Gammon MD, Terry MB, et al. Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 2007 28: 2548 2551.
6. Chen Q, Samaranayake LP, Zhen X, Luo G, Nie M, Li B. Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis. Oral Oncol 1999 35: 548 553.
7. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, Gu J. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer 2008 112: 2467 2474.
8. Anonymous. Risk loci, biological candidates and biomarkers. Nat Genet 2008 40: 257.
9. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997 34: 577 582.
10. Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003 63: 4327 4330.
11. Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003 170: 132 138.
12. Lin YC, Huang HI, Wang LH, et al. Polymorphisms of COX-2-765G>C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol 2008 44: 798 804.
13. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004 96: 1030 1036.
14. Liu K, Muse SV. PowerMarker: an integrated analysis environment for genetic marker analysis. Bioinformatics 2005 21: 2128 2129.
15. Gormus U, Ergen A, Yaylim-Eraltan I, et al. Fas-1377 A/G polymorphism in lung cancer. In Vivo 2007 21: 663 666.
16. Park SH, Choi JE, Kim EJ, et al. Polymorphisms in the FAS and FASL genes and risk of lung cancer in a Korean population. Lung Cancer 2006 54: 303 308.
17. Zhang X, Miao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005 42: 479 484.
18. Zhang B, Sun T, Xue L, et al. Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis 2007 28: 1067 1073.
19. Kang S, Dong SM, Seo SS, Kim JW, Park SY. FAS-1377 G/A polymorphism and the risk of lymph node metastasis in cervical cancer. Cancer Genet Cytogenet 2008 180: 1 5.
20. Nelson HH, Kelsey KT, Bronson MH, Mott LA, Karagas MR. Fas/APO-1 promoter polymorphism is not associated with non-melanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2001 10: 809 810.
21. Wang LE, Cheng L, Spitz MR, Wei Q. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 2003 42: 1 8.
22. Zoodsma M, Nolte IM, Schipper M, et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre) neoplastic cervical disease. Int J Gynecol Cancer 2005 15 (Suppl. 3 282 290.
23. Liu T, Laurell C, Selivanova G, Lundeberg J, Nilsson P, Wiman KG. Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis. Cell Death Differ 2007 14: 411 421.
24. Tilakaratne WM, Iqbal Z, Teh MT, et al. Upregulation of HIF-1alpha in malignant transformation of oral submucous fibrosis. J Oral Pathol Med 2008 37: 372 377.
25. Higgins DF, Kimura K, Iwano M, Haase VH. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 2008 7: 1128 1132.
26. Bozova S, Elpek GO. Hypoxia-inducible factor-1alpha expression in experimental cirrhosis: correlation with vascular endothelial growth factor expression and angiogenesis. APMIS 2007 115: 795 801.
27. Galanis A, Pappa A, Giannakakis A, Lanitis E, Dangaj D, Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett 2008 266: 12 20.
28. Gillenwater AM, Zhong M, Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007 6: 2967 2975.
29. Muraki Y, Yoshioka C, Fukuda J, Haneji T, Kobayashi N. Immunohistochemical detection of Fas antigen in oral epithelia. J Oral Pathol Med 1997 26: 57 62.
30. Schepman KP, van der Meij EH, Smeele LE, van der Waal I. Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands. Oral Oncol 1998 34: 270 275.
31. Silverman S Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer 1984 53: 563 568.
32. Trejaut JA, Tsai ZU, Lee HL, Chen ZX, Lin M. Cytokine gene polymorphisms in Taiwan. Tissue Antigens 2004 64: 492 499.
33. Kang SH, Shin D. The size of the chi-square test for the Hardy-Weinberg law. Hum Hered 2004 58: 10 7.
34. Lai HC, Lin WY, Lin YW, et al. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene-gene interaction. Gynecol Oncol 2005 99: 113 118.